Lataa...
Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has...
Tallennettuna:
| Julkaisussa: | Onco Targets Ther |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452813/ https://ncbi.nlm.nih.gov/pubmed/31040693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S141040 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|